Loading
Anhedonia / Psilocybin / Emotional Blunting · Phase 1 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 1 randomized controlled trial registered but not yet recruiting. It will evaluate whether a single 25 mg dose of psilocybin, compared with placebo, improves anhedonia and emotional blunting in adults with major depressive disorder on SSRI/SNRI therapy, measured by clinical questionnaire and fMRI-assessed brain connectivity. No results are currently available.
Phase 1, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Anhedonia, Emotional Blunting; age from 18 Years; to 65 Years. Intervention: Psilocybin. Compared with: Control — Placebo Comparator. n = 90. 1 site: United States.
This is a planned Phase 1 randomized controlled trial registered but not yet recruiting. It will evaluate whether a single 25 mg dose of psilocybin, compared with placebo, improves anhedonia and emotional blunting in adults with major depressive disorder on SSRI/SNRI therapy, measured by clinical questionnaire and fMRI-assessed brain connectivity. No results are currently available.
Phase 1 design limits scope to safety and preliminary efficacy; larger Phase 2/3 trials would be needed to establish clinical benefit.
This trial will provide early safety and signal data on psilocybin for treatment-resistant anhedonia in depression. Results should not guide practice until the trial completes and results are published.
Phase 1 trial with planned enrollment and no results reported; registry record only describes study design and intended outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This trial will provide early safety and signal data on psilocybin for treatment-resistant anhedonia in depression. Results should not guide practice until the trial completes and results are published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07607938). This is a study registration, not published results. Lead sponsor: NYU Langone Health. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 90 participants (ESTIMATED). Conditions: Anhedonia, Emotional Blunting. Interventions: DRUG: Psilocybin; DRUG: Placebo. Primary outcome measures: Change in Dimensional Anhedonia Rating Scale (DARS) Score , Baseline (Week -3), End of Study (Week 8); Change in Fronto-Striatal Connectivity (pgACC-NAcc FC) , Baseline (Week -3), End of Study (Week 8). Brief summary: This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting. The study will test whether a single 25 mg dose of psilocybin, compared with placebo, can improve these symptoms and improve the function of brain circuits involved in reward and motivation. Researchers will measure changes using brain imaging (fMRI) and clinical questionnaires, including the Dimensional Anhedonia Rating Scale (DARS).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.